Navigation Links
Late Breaking Data Released at ADA Showed that the Investigational,Use of Januvia and Metformin as Initial Combination Therapy,Provided Significant Glucose Lowering Efficacy over 54 Weeks in,Patients with Type 2 Diabetes

ose excursion following an oral glucose load or a meal. In studies with healthy subjects, JANUVIA did not lower blood glucose or cause hypoglycemia. Cardiac Electrophysiology In a randomized, placebo-controlled crossover study, 79 healthy subjects were administered a single oral dose of JANUVIA 100 mg, JANUVIA 800 mg (8 times the recommended dose), and placebo. At the recommended dose of 100 mg, there was no effect on the QTc interval obtained at the peak plasma concentration, or at any other time during the study. Following the 800 mg dose, the maximum increase in the placebo-corrected mean change in QTc from baseline was observed at 3 hours postdose and was 8.0 msec. This increase is not considered to be clinically significant. At the 800 mg dose, peak sitagliptin plasma concentrations were approximately 11-fold higher than the peak concentrations following a 100 mg dose. In patients with type 2 diabetes administered JANUVIA 100 mg (N=81) or JANUVIA 200 mg (N=63) daily, there were no meaningful changes in QTc interval based on ECG data obtained at the time of expected peak plasma concentration. 12.3 Pharmacokinetics The pharmacokinetics of sitagliptin has been extensively characterized in healthy subjects and patients with type 2 diabetes. After oral administration of a 100 mg dose to healthy subjects, sitagliptin was rapidly absorbed, with peak plasma concentrations (median Tmax) occurring 1 to 4 hours postdose. Plasma AUC of sitagliptin increased in a dose-proportional manner. Following a single oral 100 mg dose to healthy volunteers, mean plasma AUC of sitagliptin was 8.52 ?M-hr, Cmax was 950 nM, and apparent terminal half-life (t1/2) was 12.4 hours. Plasma AUC of sitagliptin increased approximately 14% following 100 mg doses at steady-state compared to the first dose. The intra-subject and inter-subject coefficients of variation for sitagliptin AUC were small (5.8% and 15.1%). The pharmacokinetics o
'"/>




Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32

Related medicine technology :

1. VeroScience Late-Breaking Abstract on Cycloset (A Quick Release Formulation of Bromocriptine Mesylate) Accepted for Poster Presentation at American Diabetes Association 67th Scientific Sessions
2. Pilot Phase 3 Results of NovaCardias KW-3902 for Acute Congestive Heart Failure Presented at Late-Breaking Session of Heart Failure Congress 2007
3. Breaking Multi-Center Study: Masimo SET Pulse Oximetry Technology Shown to Significantly Lower Instances of Severe Retinopathy of Prematurity in Extremely Low Birth Weight Infants
4. Bentley Late Breaking Abstract Accepted for Poster Presentation at American Diabetes Association Scientific Sessions
5. Cougar Biotechnology Presents Positive CB7630 Clinical Data at AACR Annual Meeting Late-Breaking Clinical Trials Session
6. Everest Data on Short- and Long-Term Use of Otsukas Investigational Novel Treatment, Tolvaptan, Published in Journal of the American Medical Association and Featured in ACCs Late Breaking Clinical Trials
7. Lupus Foundation of America Statement on Results for Clinical Study of CellCept Released by Aspreva Pharmaceutical Company
8. An Investigational Study Released at ADA Showed that Initial Combination Therapy with Januvia (sitagliptin) and Metformin Led to Improvement in Markers of Beta Cell Function in Patients with Type 2 Diabetes
9. Amlodipine and Olmesartan Study Results Released;Late Breaker Presented at American Society of Hypertension Twenty-Second Annual Scientific Meeting (ASH 2007)
10. Amlodipine and Olmesartan Study Results Released; Late Breaker Presented at American Society of Hypertension Twenty-Second Annual Scientific Meeting (ASH 2007)
11. New Anti-Rejection Medication 6-Month Results for Heart Transplant Recipients to Be Released at International Heart and Lung Transplant Meeting
Post Your Comments:
(Date:9/3/2015)...  Four financial reasons to reduce pressure ulcers ... by Leaf Healthcare, Inc . According ... (AHRQ), pressure ulcers cost the US healthcare ... addition to direct treatment related costs, pressure ulcers ... impact hospital performance metrics. On top of the ...
(Date:9/3/2015)... 2015 Research and Markets ( http://www.researchandmarkets.com/research/4q3mv2/investigation ) ... on China Olmesartan Market, 2010-2019" report to their ... successfully developed by Sankyo Pharmaceuticals Co., Ltd and was ... was approved by FDA to enter the American market ... drug in the world after it succeeded in the ...
(Date:9/3/2015)... Sep. 03, 2015 Research ... of the "Investigation Report on China,s Bromhexine Market, ... air pollution worsens, the incidence of respiratory disease keeps ... drugs. Bromhexine, a semisynthetic derivative of vasicine, is a ... and asthma associated with viscid or excessive mucus. It ...
Breaking Medicine Technology:Four Financial Reasons to Reduce Pressure Ulcer Incidents: Leaf Healthcare Releases White Paper on Direct and Indirect Costs Associated with Pressure Ulcers 2Four Financial Reasons to Reduce Pressure Ulcer Incidents: Leaf Healthcare Releases White Paper on Direct and Indirect Costs Associated with Pressure Ulcers 3China Olmesartan Investigation Market Report 2010-2019 2China Bromhexine Market Report 2015-2019 2
(Date:9/3/2015)... ... September 03, 2015 , ... Hope ... open for spring 2016. Scholarships are awarded two times each year to spouses ... is a national nonprofit dedicated to restoring a sense of self, restoring the ...
(Date:9/3/2015)... ... September 03, 2015 , ... Advice columnist, professional life coach ... book, “Stop Wasting Your Time Blaming Others for Your Life.” , Released just ... overcoming life’s obstacles by taking full responsibility for one’s life shares 15 important ...
(Date:9/3/2015)... (PRWEB) , ... September 03, ... ... Washington, a leading provider of comprehensive eating disorder treatment for adults and ... today that Ileana Calinoiu, MD has joined the medical treatment team. As ...
(Date:9/3/2015)... ... September 03, 2015 , ... ... cost increases for fully insured employer-sponsored health insurance plans, more employers are moving ... according to data released from the 2014 United Benefit Advisors (UBA) Health Plan ...
(Date:9/3/2015)... ... September 03, 2015 , ... ProScrub is a set of automated tools that ... and custom speed effects without the use of keyframes. Utilize ProScrub's powerful sliders ... tools are perfect complements to energetic video productions. ProScrub is a Final ...
Breaking Medicine News(10 mins):Health News:Hope For The Warriors Spouse/Caregiver Scholarships Now Open for Spring 2016 2Health News:Popular Advice Columnist Shares Her Path to Overcoming Personal Trials in Debut Book 2Health News:Popular Advice Columnist Shares Her Path to Overcoming Personal Trials in Debut Book 3Health News:Ileana Calinoiu, MD Joins Eating Recovery Center of Washington Medical Treatment Team 2Health News:Ileana Calinoiu, MD Joins Eating Recovery Center of Washington Medical Treatment Team 3Health News:Self-Funded Pharmacy Plans Becoming More Popular Among Large Employers 2Health News:Self-Funded Pharmacy Plans Becoming More Popular Among Large Employers 3Health News:Self-Funded Pharmacy Plans Becoming More Popular Among Large Employers 4Health News:FCPX Effects Developer Releases ProScrub for Final Cut Pro X 2
... Pharmasset, Inc.,(Nasdaq: VRUS ) management will present ... being held from May 19-20, 2008 at the Le,Meridien ... Chief Executive Officer, will provide an overview of the,company ... in the Zephyr Salon., To access a simultaneous ...
... Foundation to celebrate,scientific advancements that have fueled longer life ... To celebrate,remarkable progress in treating cystic fibrosis -- ... the Cystic Fibrosis Foundation,to join the company as honored ... Life expectancy for people with CF has more than ...
... Company Prepares for, Potential 2008 Launch of MOXATAG; Keflex Product Sales ... ... in Quarter, GERMANTOWN, Md., May 13 MiddleBrook,Pharmaceuticals, Inc. (Nasdaq: ... anti-infective products, today,announced financial and operational results for the quarter ended ...
... impact EPA,s clean air regulations, researchers say , , TUESDAY, ... particles, such as those found in windblown dust or ... not appear to be linked to hospital admissions, a ... for short, is between 2.5 and 10 micrometers or ...
... studies report, , , TUESDAY, May 13 (HealthDay News) -- New ... breast cancer risk. , The bad news is a ... with breast cancer face an increased risk of breast cancer ... according to a study in the May 13 issue of ...
... used to treat a rare but well-known genetic disorder may ... with potentially lethal enlarged hearts, due mainly to high blood ... The common denominator in both phenylketonuria (PKU) and cardiac hypertrophy ... coworker helps break down the molecule phenylalanine whose buildup is ...
Cached Medicine News:Health News:Pharmasset to Present at the Rodman & Renshaw Healthcare Conference on Tuesday, May 20th 2Health News:Cystic Fibrosis Foundation President Rings Bell to Close New York Stock Exchange 2Health News:MiddleBrook Pharmaceuticals Reports First Quarter 2008 Results 2Health News:MiddleBrook Pharmaceuticals Reports First Quarter 2008 Results 3Health News:MiddleBrook Pharmaceuticals Reports First Quarter 2008 Results 4Health News:MiddleBrook Pharmaceuticals Reports First Quarter 2008 Results 5Health News:MiddleBrook Pharmaceuticals Reports First Quarter 2008 Results 6Health News:MiddleBrook Pharmaceuticals Reports First Quarter 2008 Results 7Health News:MiddleBrook Pharmaceuticals Reports First Quarter 2008 Results 8Health News:MiddleBrook Pharmaceuticals Reports First Quarter 2008 Results 9Health News:MiddleBrook Pharmaceuticals Reports First Quarter 2008 Results 10Health News:MiddleBrook Pharmaceuticals Reports First Quarter 2008 Results 11Health News:MiddleBrook Pharmaceuticals Reports First Quarter 2008 Results 12Health News:MiddleBrook Pharmaceuticals Reports First Quarter 2008 Results 13Health News:No Link Between Coarse Air Pollution, Hospitalizations 2Health News:Familial Breast Cancer Risk Lasts a Lifetime for Sisters 2Health News:Familial Breast Cancer Risk Lasts a Lifetime for Sisters 3Health News:Drug therapy for PKU reverses heart damage 2Health News:Drug therapy for PKU reverses heart damage 3Health News:Drug therapy for PKU reverses heart damage 4
... The OMEGA 180 features a wide range ... Small and Variable Pupil Control (U.S. Patent ... sizes down to 1.2mm. Heine's unique Diffuser ... making learning BIO easier, and simplifying difficult ...
... 2006 is a long-term Transtelephonic dual ... This device is the solution of ... and their correlation to the patient's ... provides 2 lead loop recording information ...
The latest addition to Aerotels Transtelephonic ECG product line, HeartOne™ is a unique miniaturized single-lead, 4-event recorder/transmitter designed for transmission on cellular (GSM) and an...
... For General Practitioners (GP'S) ... ECGs by phone to a ... 2.5 seconds per lead and ... as rhythm lead. Sequentially transmits ...
Medicine Products: